RESUMEN
Ulcerative colitis (US) is a chronic disease of unknown etiology. It is incurable and its clinical course is intermittent, characterized by periods of remission and relapse. The prevalence and incidence of the disease has been increasing worldwide. The update presented herein includes the participation of healthcare professionals, decision-makers, and a representative of the patients, all of whom declared their conflicts of interest. Answerable clinical questions were formulated, and the outcomes were graded. The information search was conducted on the Medline/PubMed, Embase, Epistemonikos, and LILACS databases, and covered grey literature sources, as well. The search was updated on November 30, 2020, with no restrictions regarding date or language. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) classification system was implemented to establish the strength of the recommendation and quality of evidence. A formal consensus was developed, based on the RAND/UCLA methodology and the document was peer reviewed. The short version of the Clinical Practice Guidelines for the Treatment of Ulcerative Colitis in the Adult Population is presented herein, together with the supporting evidence and respective recommendations. In mild-to-moderate UC, budesonide MMX is an option when treatment with 5-ASA fails, and before using systemic steroids. In moderate-to-severe UC, infliximab, adalimumab, vedolizumab, ustekinumab, and tofacitinib can be used as first-line therapy. If there is anti-TNF therapy failure, ustekinumab and tofacitinib provide the best results. In patients with antibiotic-refractory pouchitis, anti-TNFs are the treatment of choice.
Asunto(s)
Colitis Ulcerosa , Adalimumab/uso terapéutico , Adulto , Colitis Ulcerosa/tratamiento farmacológico , Humanos , Infliximab/uso terapéutico , Inhibidores del Factor de Necrosis Tumoral , Ustekinumab/uso terapéuticoRESUMEN
Muchos de los hallazgos del diagnóstico antenatal de patología urológica son inespecíficos y sólo nos permiten diferenciar pacientes con un mayor riesgo de infección urinaria o de perder función renal. El hecho de identificar un uréter en la ecografía prenatal es un hallazgo inespecífico, que aún no tenemos claro qué significa y qué pronóstico tiene para nuestros pacientes. A partir de noviembre de 1999, tenemos un protocolo prospectivo para el seguimiento y manejo de pacientes con diagnóstico antenatal de patología urológica. Se revisó en forma retrospectiva los pacientes en que hubo dilatación ureteral en la ecografía prenatal.180 pacientes han sido referidos y seguidos según protocolo. En 21 pacientes (11.7 por ciento) se ha hecho diagnóstico de dilatación ureteral en la ecografía prenatal. Once hombres y 10 mujeres. Los diagnósticos postnatales de estos pacientes fueron: 4 pacientes con doble sistema pieloureteral; 2 pacientes con megauréteres; 1paciente con una cloaca; 5 pacientes con dilataciones transitorias; 2 pacientes con ureterocele en sistemaúnico; 1 paciente con reflujo vesicoureteral en un sistema único y con un riñón multicístico en el contralateral; 1 paciente con valvas de uretra posterior y 5 pacientes con obstrucción pieloureteral. Un total de 13 pacientes de los 21 requirieron cirugía (62por ciento) y 8 se manejaron médicamente (38.09 por ciento).El hecho de identificar el uréter dilatado en la ecografía prenatal nos permite identificar una población prenatal de riesgo, ya que un 57,1 por ciento de nuestros pacientes requirieron de cirugía. Llama la atención que 5 pacientes en que se vio el uréter dilatado en la ecografía prenatal, terminaron operándose de obstrucción pieloureteral. Esto apoya la hipótesis de que estas obstrucciones sean secundarias a dilataciones ureterales prenatales. El consejo prenatal tiene que ser dado con cautela y por gente con experiencia, ya que a pesar de existir un riesgo elevado de cirugía...
Prenatal diagnosis is usually non specific and only allows for early detection of patients with a higher risk of developing urinary tract infections or loss of renal function. The identification of the ureter in a prenatal ultrasound is a nonspecific finding. The relevance of this is unknown. A prospective protocol for the management and follow up of patients with antenatal diagnosis of urologicmal formations was started in 1999. We retrospectively review our patients who presented a ureteral dilatation in the antenatal ultrasound.180 patients were referred and follow up was carried out according to protocol. 21 patients (11.7 percent) had ureteral dilatation on the prenatal ultrasound, 11 male and 10 female. The following post natal diagnoses were registered: 4 patients had a duplex kidney, 2 patients had megaureter, 1 patient had a cloaca, 5 patients had transitory dilatations, 2 patients had ureterocele in an single system, 1 patient had VUR in a single system and a contralateral muticystic kidney, 1 patient had posterior urethral valves, and 5 patients had ureteropelvic obstruction.13 of 21 patients required surgery (62 percent), the other 8 required only prophylaxis and follow up (38.09 percent). Being able to identify a dilated ureter in an prenatal ultrasound allowed us to define a high risk group, in which 62 percent required surgery. Of the patients in this group, it is noteworthy that 5 patients in whom a dilated ureter was visualized were operated on for ureteropelvic obstruction. This fact supports the idea that obstructions are secondary to antenatal ureteral dilations. Antenatal advice should be given carefully and by experienced personnel because, although there was a high percentage of surgery in this group, there was also a group of patients that only required antibiotics prophylaxis and image monitoring.
Asunto(s)
Humanos , Masculino , Femenino , Embarazo , Dilatación Patológica/diagnóstico , Enfermedades Ureterales/diagnóstico , Ultrasonografía Prenatal , Estudios de Seguimiento , Obstrucción Ureteral/etiologíaRESUMEN
INTRODUCTION: Carcinoid tumors are rare, most of the publications are case reports and the clinical series are uncommon. The quality of life and survival time of these patients depend on the adequate control of tumor growth and good palliation of their symptoms. AIMS: The purpose of this study is to inform epidemiological data and forms of management for these tumors and the Carcinoid Syndrome at the National Institute of Cancerology (INCan) at Mexico City in the last 15 years. METHODS: A retrospective review of the clinical records of patients diagnosed and treated at the INCan with carcinoid tumors from 1982 to 1997 was performed. RESULTS: The most common origin place was the gastrointestinal tract (GI), and the majority involved the right colon and the appendix. The longest survivors were patients with tumors originated in the appendix, tumors smaller than 2 cm or localized. At the time of diagnosis 47% of patients had metastatic disease that was also a poor prognostic factor. The experience in our hospital seem to support the use of interferon alone or in combination with octreotide or debulking surgery for the palliation of carcinoid syndrome. CONCLUSIONS: Carcinoid tumors are rare, and have a slow growth and less aggressive biological nature than noncarcinoid tumors. Treatment should be focused on trying to cure the small or localized lesions or to find the best palliative method for those symptomatic advanced lesions.
Asunto(s)
Tumor Carcinoide/terapia , Neoplasias del Sistema Digestivo/terapia , Síndrome Carcinoide Maligno/terapia , Adulto , Anciano , Antineoplásicos/uso terapéutico , Antineoplásicos Hormonales/uso terapéutico , Tumor Carcinoide/diagnóstico , Tumor Carcinoide/mortalidad , Neoplasias del Sistema Digestivo/diagnóstico , Neoplasias del Sistema Digestivo/mortalidad , Femenino , Humanos , Interferones/uso terapéutico , Masculino , Síndrome Carcinoide Maligno/diagnóstico , Síndrome Carcinoide Maligno/mortalidad , Persona de Mediana Edad , Metástasis de la Neoplasia , Octreótido/uso terapéutico , Cuidados Paliativos , Pronóstico , Estudios Retrospectivos , Factores de Tiempo , Tomografía Computarizada por Rayos XRESUMEN
OBJECTIVE: Determine the general features of primary gallbladder carcinoma (GBC), the diagnostic procedure and the current management as well as to analyze the experience at the National Institute of Cancer in Mexico City (INCan). INTRODUCTION: GBC is a rare and frequently lethal disease. The majority of patients are diagnosed at late clinical stages when the prognosis is poor. However in recent years several investigators have shown that radical procedures increase survival. MATERIAL AND METHODS: A review of relevant articles regarding epidemiological features, laboratory and imaging studies together with the actual form of management according to the stage at diagnosis was made. A review of clinical records of patients with GBC at the INCan in the last 10 years was also made. RESULTS: The prognosis of GBC carcinoma depends of the stage at the time of diagnosis, tumors confined to the gallbladder (Nevin I-III) have better prognosis than those presented with lymphadenopathy or liver invasion. Actually the surgical procedure most accepted is wedge liver resection and lymphadenectomy, because it seems to improve survival. At the INCan one hundred patients were analyzed of which only six were diagnosed with lesion Nevin I all alive with a mean follow up of 33 months, with lesions Nevin II five out of 13 are alive and were treated with wedge liver resection or radiotherapy, lesion Nevin III only 4 alive and received radiotherapy. Patients with lesions Nevin IV and V have the poorest prognosis. CONCLUSION: GBC is a highly lethal disease. Early diagnosis make possible to perform radical resections and improve survival.